Literature DB >> 10070893

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer.

H M McDaid1, M T Cairns, R J Atkinson, S McAleer, D P Harkin, P Gilmore, P G Johnston.   

Abstract

The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070893      PMCID: PMC2362667          DOI: 10.1038/sj.bjc.6690149

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Cancer Incidence in Five Continents. Age-specific and standardized incidence rates.

Authors:  S L Whelan; J Ferlay
Journal:  IARC Sci Publ       Date:  1992

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Purification and properties of rabbit skeletal muscle adenosine 3',5'-monophosphate-dependent protein kinases.

Authors:  E M Reimann; D A Walsh; E G Krebs
Journal:  J Biol Chem       Date:  1971-04-10       Impact factor: 5.157

4.  An adenosine 3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle.

Authors:  D A Walsh; J P Perkins; E G Krebs
Journal:  J Biol Chem       Date:  1968-07-10       Impact factor: 5.157

Review 5.  Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy.

Authors:  Y S Cho-Chung
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

Review 6.  The cAMP-dependent protein kinases and cAMP signal transduction.

Authors:  S J Beebe
Journal:  Semin Cancer Biol       Date:  1994-08       Impact factor: 15.707

7.  Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary.

Authors:  A P Wilson
Journal:  J Natl Cancer Inst       Date:  1984-03       Impact factor: 13.506

8.  Characterization of a human ovarian carcinoma cell line, OTN 14, derived from a mucinous cystadenocarcinoma.

Authors:  C C van Niekerk; L G Poels; P H Jap; D F Smeets; C M Thomas; F C Ramaekers; G P Vooijs
Journal:  Int J Cancer       Date:  1988-07-15       Impact factor: 7.396

9.  Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological features.

Authors:  B J Simpson; A D Ramage; M J Hulme; D J Burns; D Katsaros; S P Langdon; W R Miller
Journal:  Clin Cancer Res       Date:  1996-01       Impact factor: 12.531

10.  Expression of the chicken GATA factor family during early erythroid development and differentiation.

Authors:  M W Leonard; K C Lim; J D Engel
Journal:  Development       Date:  1993-10       Impact factor: 6.868

View more
  13 in total

1.  Alternative promoter usage and differential expression of multiple transcripts of mouse Prkar1a gene.

Authors:  Abdul Rouf Banday; Shafquat Azim; Mohammad Tabish
Journal:  Mol Cell Biochem       Date:  2011-06-03       Impact factor: 3.396

Review 2.  Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes.

Authors:  Fausto J Rodriguez; Constantine A Stratakis; D Gareth Evans
Journal:  Acta Neuropathol       Date:  2011-12-31       Impact factor: 17.088

3.  Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

Authors:  H Wang; Q Cai; X Zeng; D Yu; S Agrawal; R Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 4.  The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis.

Authors:  A J Bauer; C A Stratakis
Journal:  J Med Genet       Date:  2005-06-15       Impact factor: 6.318

5.  Antisense DNAs as multisite genomic modulators identified by DNA microarray.

Authors:  Y S Cho; M K Kim; C Cheadle; C Neary; K G Becker; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

6.  PRKAR1A gene analysis and protein kinase A activity in endometrial tumors.

Authors:  A Tsigginou; E Bimpaki; M Nesterova; A Horvath; S Boikos; C Lyssikatos; C Papageorgiou; C Dimitrakakis; A Rodolakis; C A Stratakis; A Antsaklis
Journal:  Endocr Relat Cancer       Date:  2012-06-18       Impact factor: 5.678

7.  Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model.

Authors:  Virginie Follin-Arbelet; Peter O Hofgaard; Harald Hauglin; Soheil Naderi; Anders Sundan; Rune Blomhoff; Bjarne Bogen; Heidi K Blomhoff
Journal:  BMC Cancer       Date:  2011-07-18       Impact factor: 4.430

8.  Protein kinase A type I activates a CRE-element more efficiently than protein kinase A type II regardless of C subunit isoform.

Authors:  Øystein Stakkestad; Anja C V Larsen; Anne-Katrine Kvissel; Sissel Eikvar; Sigurd Ørstavik; Bjørn S Skålhegg
Journal:  BMC Biochem       Date:  2011-02-08       Impact factor: 4.059

9.  Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion.

Authors:  Andrew J McKenzie; Shirley L Campbell; Alan K Howe
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

10.  Implementing fluorescence anisotropy screening and crystallographic analysis to define PKA isoform-selective activation by cAMP analogs.

Authors:  Simon H J Brown; Cecilia Y Cheng; S Adrian Saldanha; Jian Wu; Howard B Cottam; Banumathi Sankaran; Susan S Taylor
Journal:  ACS Chem Biol       Date:  2013-09-10       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.